Company Filing History:
Years Active: 2009-2012
Title: Ewa Skrzypczak-Jankun: Innovator in Modified Plasminogen Activator Inhibitor Research
Introduction
Ewa Skrzypczak-Jankun is a prominent inventor based in Sylvania, OH (US). She has made significant contributions to the field of biochemistry, particularly in the development of modified plasminogen activator inhibitors. With a total of 2 patents, her work focuses on enhancing therapeutic applications for various medical conditions.
Latest Patents
Ewa's latest patents include innovations related to modified plasminogen activator inhibitor type-1 (PAI-1) molecules. The first patent describes a modified PAI-1 molecule that exhibits an increased in vivo half-life while being deficient in certain functional activities compared to the wild-type PAI-1 protein. This invention also encompasses pharmaceutical compositions that utilize these modified molecules for treatment purposes. The second patent builds upon this concept, detailing a modified PAI-1 in which specific amino acid residues are replaced to form intramolecular disulfide bonds, thereby increasing its half-life. This invention has potential applications in inhibiting angiogenesis and treating conditions such as psoriasis, chronic inflammation, and cardiovascular diseases.
Career Highlights
Ewa has worked at notable institutions, including the University of Toledo and the Medical College of Ohio. Her research has significantly advanced the understanding of PAI-1 and its implications in various diseases.
Collaborations
Ewa has collaborated with esteemed colleagues, including Jerzy Jankun and Steven H Selman, to further her research and innovations in the field.
Conclusion
Ewa Skrzypczak-Jankun's contributions to the development of modified plasminogen activator inhibitors highlight her role as a leading inventor in biochemistry. Her work continues to pave the way for new therapeutic strategies in treating complex medical conditions.